HLB글로벌

003580KOSPI종합 소매업

52.6 / 100

Reference Date: 2026-07-24

Financial Score15.5 / 40

News Sentiment20.1 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 19.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Global operates primarily in media commerce and resource development, manufacturing and selling products such as automotive accessories, perfumes, cosmetics, food, and beverages. Through its subsidiaries, the company diversifies into media commerce, cosmetics, food and beverage, and bio-healthcare sectors, with major revenue contributions from media commerce and food segments.

Number of Employees

170people

Average Salary

42.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 16.074.0Point

PBR

0.81Industry Average 0.461.0Point

1.8x industry avg (risky)

ROE

-10.45Industry Average 1.840.0Point

Well below industry avg

Debt Ratio

5.42Industry Average 35.578.0Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲12.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼49.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -21.8% (improving, 3yr)

Detailed News Sentiment

19 totalPositive 13Neutral 0Negative 6Average Sentiment Score 80.3

Positive
HLB라이프케어 '피코링', 인바디와 협업...연속혈당측정기 B2B 공...
HLB라이프케어의 피코링과 인바디의 협업으로 헬스케어 서비스 혁신 및 시장 확장 기대.
Positive
HLB라이프케어, 인바디헬스케어와 '피코링 판매' 협업
HLB글로벌의 HLB라이프케어가 인바디헬스케어와의 협업으로 피코링 판매 확대 기대.
Positive
HLB 자회사 이뮤노믹, 항암백신 'ITI-5000' 미국 임상 1상 ...
HLB글로벌 자회사 이뮤노믹의 항암백신 'ITI-5000'이 미국 임상 1상에 진입하며 긍정적인 임상 개발 진전을 보여주고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 1,211Won52-week high 2,64052-week low 1,090

1-month return0.0Point

1m -19.32% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0